| Citation: |
XU Gang, GAO Yi, YAN Maosheng. Expression of miR-155/PTEN Axis in Hepatocellular Carcinoma and Its Mechanism[J]. Cancer Research on Prevention and Treatment, 2018, 45(2): 67-72. DOI: 10.3971/j.issn.1000-8578.2018.17.0931
|
To detect the expression and the function of microRNA-155(miR-155) in hepatocellular carcinoma(HCC) tissuse, and to elucidate related mechanism.
miR-155 expression was examined in 30 pairs of HCC and adjacent normal tissues by quantitative reverse transcription PCR(qRT-PCR). HCC cells were treated with miR-155 mimic to upregulate miR-155 expression in vitro. CCK-8 and Transwell assays were used to analyze the changes in cell proliferation and migration. PTEN was predicted to be the direct target of miR-155 by bioinformatics analysis and luciferase reporter assay. The prognostic value of miR-155 and PTEN in patients with HCC were assessed through cBioPortal database.
miR-155 was significantly upregulated in HCC tissues compared with that in adjacent normal tissues (P < 0.0001). Overexpression of miR-155 was associated with worse disease free survival (P=0.021). Elevated expression of miR-155 promoted the proliferation and migration of hepatocellular carcinoma cells. Furthermore, miR-155 directly repressed PTEN expression, which enhanced PI3K signaling pathway. Deletion of PTEN depicted worse disease free survival in patients with HCC (P=0.0133).
The axis of miR-155/PTEN accelerates HCC progression.
| [1] |
吕桂帅, 陈磊, 王红阳.我国肝癌研究的现状与前景[J].生命科学, 2015, 27(3): 237-48. http://www.doc88.com/p-7116955320778.html
Lyu GS, Chen L, Wang HY. Research progress and prospect of liver cancer in China[J]. Sheng Ming Ke Xue, 2015, 27(3): 237-48. http://www.doc88.com/p-7116955320778.html
|
| [2] |
Bruix J, Sherman M, Practice Guidelines Committee, et al. Management of hepatocellular carcinoma[J]. Hepatology, 2005, 42(5): 1208-36. doi: 10.1002/hep.v42:5
|
| [3] |
Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function[J]. Cell, 2004, 116(2): 281-97. doi: 10.1016/S0092-8674(04)00045-5
|
| [4] |
Huang X, Shen Y, Liu M, et al. Quantitative proteomics reveals that miR-155 regulates the PI3K-AKT pathway in diffuse large B-cell lymphoma[J]. Am J Pathol, 2012, 181(1): 26-33. doi: 10.1016/j.ajpath.2012.03.013
|
| [5] |
Kong X, Liu F, Gao J. MiR-155 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells through the activation of PI3K/SGK3/β-catenin signaling pathways[J]. Oncotarget, 2016, 7(40): 66051-60. https://www.researchgate.net/profile/Yun_Fei_Yuan/citations?sorting=recent&page=3
|
| [6] |
黄少军, 汪晶晶, 江华, 等.结肠癌组织中miR-155表达在预测复发转移中的价值及其与血清CEA的相关性[J].肿瘤防治研究, 2014, 41(6): 606-9. doi: 10.3971/j.issn.1000-8578.2014.06.021
Huang SJ, Wang JJ, Jiang H, et al. Value of miR-155 Expression in Forecast of Recurrence or Metastasis and Its Correlation with Serum CEA Levels after Operation[J]. Zhong Liu Fang Zhi Yan Jiu, 2014, 41 (6): 606-9. doi: 10.3971/j.issn.1000-8578.2014.06.021
|
| [7] |
高轶, 付圣灵, 江文洋, 等. pⅢ期非小细胞肺癌中miR-155的表达与预后关系的研究[J].中国肺癌杂志, 2014, 17(5): 417-23. doi: 10.3779/j.issn.1009-3419.2014.05.10
Gao Y, Fu SL, Jiang WY, et al. A ssociation of miR-155 expression with prognosisin in resected stage Ⅲ Non-small cell lung cancer[J]. Zhongguo Fei Ai Za Zhi, 2014, 17(5): 417-23. doi: 10.3779/j.issn.1009-3419.2014.05.10
|
| [8] |
Milella M, Falcone I, Conciatori F, et al. PTEN: Multiple Functions in Human Malignant Tumors[J]. Front Oncol, 2015, 5: 24. https://www.researchgate.net/profile/Michele_Milella/publication/273466580_PTEN_Multiple_Functions_in_Human_Malignant_Tumors/links/550b4f7e0cf265693cef73ba.pdf?origin=publication_detail
|
| [9] |
Gao Y, Fan X, Li W, et al. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124[J]. Biochem Biophys Res Commun, 2014, 446(1): 179-86. doi: 10.1016/j.bbrc.2014.02.073
|
| [10] |
Han ZB, Chen HY, Fan JW, et al. Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation[J]. J Cancer Res Clin Oncol, 2012, 138(1): 153-61. doi: 10.1007/s00432-011-1076-z
|
| [11] |
Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?[J]. Nat Rev Genet, 2008, 9(2): 102-14. doi: 10.1038/nrg2290
|
| [12] |
Wang B, Majumder S, Nuovo G, et al. Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice[J]. Hepatology, 2009, 50(4): 1152-61. doi: 10.1002/hep.23100
|
| [13] |
Zhang Y, Wei W, Cheng N, et al. Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling[J]. Hepatology, 2012, 56(5): 1631-40. doi: 10.1002/hep.25849
|
| [14] |
Li S, Zhu M, Pan R, et al. The tumor suppressor PTEN has a critical role in antiviral innate immunity[J]. Nat Immunol, 2016, 17(3): 241-9. https://www.researchgate.net/publication/287810981_The_tumor_suppressor_PTEN_has_a_critical_role_in_antiviral_innate_immunity
|
| [15] |
Vigorito E, Kohlhaas S, Lu D, et al. miR-155: an ancient regulator of the immune system[J]. Immunol Rev, 2013, 253(1): 146-57. doi: 10.1111/imr.2013.253.issue-1
|
| [16] |
Platanias LC. Mechanisms of type-Ⅰ-and type-Ⅱ-interferon-mediated signalling[J]. Nat Rev Immunol, 2005, 5(5): 375-86. doi: 10.1038/nri1604
|
| [17] |
Callegari E, Gramantieri L, Domenicali M, et al. MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches[J]. Cell Death Differ, 2015, 22(1): 46-57. doi: 10.1038/cdd.2014.136
|
| [18] |
Cheng CJ, Bahal R, Babar IA, et al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment[J]. Nature, 2015, 518(7537): 107-10. doi: 10.1038/nature13905
|
| [1] | XU Xiaoyan, XU Xianwei, WANG Hui, YANG Jinhua. Expression of PTEN and EMMPRIN in Lung Adenocarcinoma Tissues and Their Correlation with EGFR Mutation[J]. Cancer Research on Prevention and Treatment, 2017, 44(5): 324-328. DOI: 10.3971/j.issn.1000-8578.2017.05.003 |
| [2] | ZHOU Xiaolei, ZHU Chongyue, ZHANG Shiguang, ZHOU Zhiyan, LI Haichao, ZOU Wei. NDRG2 Inhibits Migration of Breast Cancer Cells Through Upregulating PTEN Expression[J]. Cancer Research on Prevention and Treatment, 2017, 44(1): 5-10. DOI: 10.3971/j.issn.1000-8578.2017.01.002 |
| [3] | HOU Xin, QIN Shukui, OU Yurong, LI Yumei, WANG Rui, QIAN Xiujuan, HOU Yueyue, WU Qiong. Expressions and Relevance of MDM2 and PTEN in Bile Duct Carcinoma[J]. Cancer Research on Prevention and Treatment, 2014, 41(06): 610-613. DOI: 10.3971/j.issn.1000-8578.2014.06.022 |
| [4] | BAI Zhi-gang, ZHANG Zhong-tao, YE Ying-jiang, WANG Shan. Expression and Prognostic Significance of Nuclear PTEN in Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2011, 38(05): 528-531. DOI: 10.3971/j.issn.1000-8578.2011.05.012 |
| [5] | LIANG Xu-dong, SHI Xiao-feng, JIA Zong-qi. Detection andSignificance of PTEN, NFκB andKi-67 in Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2010, 37(03): 326-629. DOI: 10.3971/j.issn.1000-8578.2010.03.023 |
| [6] | GE Xia, NIU Duo-Shan, CHENG Ze-nong. Expression and Significance of claudin-4 and PTEN in Endometrial Carcinoma[J]. Cancer Research on Prevention and Treatment, 2009, 36(07): 583-586. DOI: 10.3971/j.issn.1000-8578.2009.07.012 |
| [7] | WANG Dong-lin, XIE Jing-xin, SHI Gong-sheng, E Qun. Expressions of FHIT and PTEN in Brain Gliomas[J]. Cancer Research on Prevention and Treatment, 2007, 34(06): 423-424. DOI: 10.3971/j.issn.1000-8578.1303 |
| [8] | LU Yun-fei, LI Meng-yang, ZENG Jian, LIN Jin-ling. The Clinical Significance and Expression of PTEN, survivin in Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2006, 33(04): 219-221，. DOI: 10.3971/j.issn.1000-8578.421 |
| [9] | MENG Dong-yue, ZHANG Xiang-hong. Expression of PTEN in Colorectal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2006, 33(03): 183-184，. DOI: 10.3971/j.issn.1000-8578.435 |
| [10] | YANG Zhi-fang, YI Ji-lin, LI Xing-rui, LONG Wei. Expression of PTEN in Hepatocellular Carcinoma and Its Correlation with Phosphorylation of PKB/AKT[J]. Cancer Research on Prevention and Treatment, 2004, 31(12): 748-750. DOI: 10.3971/j.issn.1000-8578.1588 |
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: